MARKETERSANOFI

Rezurock (belumosudil mesylate) is an orally administered selective inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), indicated for chronic Graft vs Host Disease (cGVHD) after failure of at least two prior lines of systemic therapy. FDA approved Rezurock in 2021.

Background

HCRx purchased a right to receive royalties and milestones due from Sanofi with respect to global sales of Rezurock. The counterparty had a desire to monetize its royalty interest to help wind down an investment entity.